

Hoi [REDACTED] 5.1.2e

Ik zie net deze uitnodiging van een HSC meeting morgen over wetenschappelijk bewijs ten aanzien van rol in verspreiding van vaccinatie, met het oog op de verordening waar de EU mee gaat komen. De meeting is morgen van 13:00-15:00. Ik kan me voorstellen dat iemand van jullie team / of het RIVM hier graag bij zou willen zijn?

Hij is gericht aan de HSC members (formeel is dit [REDACTED] 5.1.2e), maar ik ga ervanuit dat ook anderen kunnen registreren. Zouden jullie kunnen laten weten of iemand uit jullie team wil/kan aansluiten?

Groet, [REDACTED] 5.1.2e

Van: [REDACTED] 5.1.2e <[REDACTED]@ec.europa.eu> <[REDACTED] 5.1.2e <[REDACTED]@ec.europa.eu>

Verzonden: donderdag 4 maart 2021 14:40

Aan: [REDACTED] 5.1.2e <[REDACTED]@ec.europa.eu>

Onderwerp: Invitation: JOINT HSC-EU NITAG COLLABORATION SCIENTIFIC EVIDENCE RELATED TO RISK OF TRANSMISSION OF SARS-CoV-2 FOLLOWING COVID-19 VACCINATION IN VIEW OF PROPOSED EU VACCINATION CERTIFICATES

Urgentie: Hoog

Dear members of the Health Security Committee,
Dear EU NITAG Collaboration members,

Please be invited to a joint HSC/EU NITAG COLLABORATION meeting already **tomorrow Friday 5th of March 13:00 – 15:00 CET** on the topic:

REVIEW OF SCIENTIFIC EVIDENCE RELATED TO RISK OF TRANSMISSION OF SARS-CoV-2 FOLLOWING COVID-19 VACCINATION IN VIEW OF PROPOSED EU VACCINATION CERTIFICATES

This webinar is **open to the HSC members and nominated EU/EEA NITAG COLLABORATION members as well as other appointed NITAG members in EU/EEA.**

Formal invitations will come through the EU HSC Secretariat at the European Commission. Please remember it is necessary to register for this meeting. Only after registering for this meeting you will receive dial-in details.

Scientific data on what is known on risk for infection and subsequent transmission of SARS-CoV-2 following vaccination will be presented from the first observational studies conducted in Denmark, Israel and United Kingdom. Following the presentations a discussion will be held on the available scientific data presented in view of the proposed vaccination certificates to possibly be used within countries, between EU/EEA countries and possibly one day globally (WHO is working in parallel with the European Commission).

This meeting is triggered by the rather urgent on-going EU discussions on vaccination certificates and their use, possibly before the summer. Apologies for the short notice.

First experience in using vaccination certificates will also be provided from Israel.

A very warm welcome to all.

13:00 – 13:05	Welcome	[REDACTED] 5.1.2e SANTE C3, EC
13:00 – 13:10	Objectives of the meeting	[REDACTED] 5.1.2e, [REDACTED] 5.1.2e, ECDC
13:10 – 13:25	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting	[REDACTED] 5.1.2e [REDACTED] 5.1.2e, Clalit Research Institute, Israel [REDACTED] 5.1.2e [REDACTED] 5.1.2e [REDACTED] 5.1.2e Harvard

		Medical School
13:25 – 13:40	Pfizer Vaccination Efficacy in Infection Prevention Based on Routine Staff Tests in Long Term Care Facilities	5.1.2e Israeli Information and Knowledge Center
13:40 – 13:55	Vaccination cards, Recovered cards, Green and Purple standards	5.1.2e 5.1.2e 5.1.2e 5.1.2e 5.1.2e 5.1.2e 5.1.2e 5.1.2e Division of Epidemiology Ministry of Health, Israel
13:55 – 14:10	ChAdOx1 nCoV-19, used in the authorised schedules provide substantial impact on transmission	5.1.2e Department of Paediatrics, University of Oxford
14:10 – 14:25	BNT162b2 mRNA Covid-19 Vaccine – high effectiveness when offered to health care workers and LTCF residents/staff	5.1.2e 5.1.2e Department of Infectious Disease Epidemiology & Prevention Infection Disease Preparedness
14:25 – 14:55	Discussion	All
14:55 – 15:00	Next steps and closure of the meeting	5.1.2e

To participate, please register using this link:

5.1.2h

Kind regards,

HSC Secretariat

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

